A new model for HIV progression finds that it spreads in a similar way to some computer worms and predicts that early treatment is key to staving off AIDS.
HIV specialists and network security experts at UCL noticed that the spread of HIV through the body using two methods - via the bloodstream and directly between cells - was similar to how some computer worms spread through both the internet and local networks respectively to infect as many computers as possible. They worked together to create a model for this 'hybrid spreading', which accurately predicted patients' progression from HIV to AIDS in a major clinical trial.
Detailed sample data from 17 HIV patients from London were used to verify the model, showing that hybrid spreading provides the best explanation for HIV progression and highlighting the benefits of early treatment.
HIV infects CD4+ T-cells, which play a vital role in the immune system and protect us from diseases. As HIV progresses, it reduces the number of active T-cells in the body until the immune system cannot function correctly, a state known as 'acquired immune deficiency syndrome' or AIDS.
Current World Health Organisation guidelines, which the UK government follows, recommend only beginning HIV treatment when the number of T-cells in the bloodstream falls below a certain level. However, the new model predicts that treatment should start as soon as possible after infection to prevent AIDS from developing in the long term.
"The number of HIV cells in the bloodstream is always relatively low, and our model shows that HIV spread through the bloodstream alone would not be enough to cause AIDS," explains co-senior author Professor Benny Chain (UCL Infection & Immunity). "It is likely that when HIV gains a foothold somewhere with a high T-cell population, such as the gut, it uses a cell-to-cell transfer mechanism to efficiently spread directly between them. As such, if HIV has already spread to an area rich in T-cells by the time treatment begins, preventing its spread through the bloodstream will not stop AIDS. Our model suggests that completely blocking cell-to-cell transfer would prevent progression to AIDS, highlighting the need to develop new treatments."
The model was inspired by similarities between HIV and computer worms such as the highly damaging 'Conficker' worm, first detected in 2008, which has infected military and police computer networks across Europe and is still active today.
"HIV and Conficker have a lot in common," says lead author Changwang Zhang (UCL Computer Science). "They both use hybrid spreading mechanisms, persist for a very long time and are incredibly difficult to eradicate. Our model enables us to explain these important properties and to predict the infection process."
Changwang's supervisor, co-author Dr Shi Zhou (UCL Computer Science) says: "Although the cybersecurity community organised an unprecedented collaboration to tackle Conficker, they still failed to eliminate Conficker from the Internet. HIV researchers face a similar problem. We hope that our new understanding of hybrid epidemics will help us to fight against Conficker and HIV."
Laboratory research led by co-senior author Dr Clare Jolly (UCL Infection & Immunity) has previously shown that some drugs are better than others at stopping HIV from spreading directly between cells. However, it is not possible to directly measure cell-to-cell spread in patients because it takes place inside internal organs.
"With this new model, we should be able to assess the effectiveness of drugs against different modes of HIV spread in real patients," explains Dr Jolly. "This could prove invaluable when interpreting the results of drug trials to understand what works and why. Using computer models to understand processes that we cannot directly observe is common in the physical sciences and supports many fundamental theories. Our model provides strong evidence that cell-to-cell spread is an important part of HIV spread, and we hope to show this directly in future animal studies."
Explore further: Identification of drug combinations that reverse HIV-1 latency